Background: Quality indicators (QIs) support measurement and improvement of ICU care; however, until 2017 there was no comprehensive, evidence-based QI set tailored to frontline adult ICU practice in Japan. Because evidence and practice evolve, periodic updating is required. We developed a Japanese ICU QI set in 2017-2018 and conducted a formal re-evaluation in 2025 to confirm current validity and update the core set.
Methods: We used a modified RAND/UCLA appropriateness method. First, an initial list of candidate QIs was generated through a systematic literature review and major clinical guidelines. Next, a multidisciplinary panel of 14 Japanese experts (including intensivists, a nurse, a physiotherapist, and a clinical engineer) rated the appropriateness of these indicators using a nine-point Likert scale (Round 1). Following Round 1, a face-to-face consensus meeting was held to discuss, refine, add, or delete indicators based on scientific evidence, clinical importance, and feasibility, followed by Round 2 to finalize the 2018 consensus set. In 2025 (Round 3), the panel re-rated all indicators from the 2018 set using the same rating and classification framework and also rated newly proposed indicators reflecting contemporary practice.
Results: The systematic review yielded 44 initial candidate QIs. After the two-round rating process and the expert panel meeting, a 2018 consensus set of 38 QIs was established (13 structure indicators, 10 process indicators, and 15 outcome indicators). In Round 3 (2025), 37 indicators remained Appropriate, whereas one indicator was reclassified as Uncertain and was not retained in the updated core set. One newly proposed indicator was rated Appropriate and added, resulting in an updated 2025 core set of 38 indicators. All selected indicators were deemed appropriate and relevant for the Japanese ICU setting by the expert panel.
Conclusions: Using a rigorous modified RAND/UCLA appropriateness method and a 2025 re-evaluation, we developed and updated a feasible, contextually adapted Japanese ICU QI set. The updated core set, with operational definitions and specified data sources, provides a foundation for national benchmarking and continuous quality improvement in Japanese ICUs. 330 words.
{"title":"Development and 2025 re-evaluation of a Japanese quality indicator set for adult intensive care: a modified RAND/UCLA Delphi study.","authors":"Junji Kumasawa, Hiroshi Okamoto, Takaki Naito, Takehiko Asaga, Masayoshi Kimura, Toru Kotani, Yasuhiro Komatsu, Takeshi Suzuki, Tetsuya Takahashi, Tetsuhiro Takei, Masaji Nishimura, Satoru Hashimoto, Hiroko Yamaguchi, Matsuyuki Doi","doi":"10.1186/s40560-026-00863-w","DOIUrl":"https://doi.org/10.1186/s40560-026-00863-w","url":null,"abstract":"<p><strong>Background: </strong>Quality indicators (QIs) support measurement and improvement of ICU care; however, until 2017 there was no comprehensive, evidence-based QI set tailored to frontline adult ICU practice in Japan. Because evidence and practice evolve, periodic updating is required. We developed a Japanese ICU QI set in 2017-2018 and conducted a formal re-evaluation in 2025 to confirm current validity and update the core set.</p><p><strong>Methods: </strong>We used a modified RAND/UCLA appropriateness method. First, an initial list of candidate QIs was generated through a systematic literature review and major clinical guidelines. Next, a multidisciplinary panel of 14 Japanese experts (including intensivists, a nurse, a physiotherapist, and a clinical engineer) rated the appropriateness of these indicators using a nine-point Likert scale (Round 1). Following Round 1, a face-to-face consensus meeting was held to discuss, refine, add, or delete indicators based on scientific evidence, clinical importance, and feasibility, followed by Round 2 to finalize the 2018 consensus set. In 2025 (Round 3), the panel re-rated all indicators from the 2018 set using the same rating and classification framework and also rated newly proposed indicators reflecting contemporary practice.</p><p><strong>Results: </strong>The systematic review yielded 44 initial candidate QIs. After the two-round rating process and the expert panel meeting, a 2018 consensus set of 38 QIs was established (13 structure indicators, 10 process indicators, and 15 outcome indicators). In Round 3 (2025), 37 indicators remained Appropriate, whereas one indicator was reclassified as Uncertain and was not retained in the updated core set. One newly proposed indicator was rated Appropriate and added, resulting in an updated 2025 core set of 38 indicators. All selected indicators were deemed appropriate and relevant for the Japanese ICU setting by the expert panel.</p><p><strong>Conclusions: </strong>Using a rigorous modified RAND/UCLA appropriateness method and a 2025 re-evaluation, we developed and updated a feasible, contextually adapted Japanese ICU QI set. The updated core set, with operational definitions and specified data sources, provides a foundation for national benchmarking and continuous quality improvement in Japanese ICUs. 330 words.</p>","PeriodicalId":16123,"journal":{"name":"Journal of Intensive Care","volume":" ","pages":""},"PeriodicalIF":4.7,"publicationDate":"2026-02-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146149977","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-02-09DOI: 10.1186/s40560-026-00861-y
Jingwei Duan, Yuanchao Shi, Yufan Du, Dilu Li, Baomin Duan, Guoxing Wang
Background: Despite advances in post-cardiac arrest (CA) care, mortality rates remain high. Intestinal dysfunction following CA is associated with adverse clinical outcomes. While laxatives might be a potential therapeutic strategy for restoring intestinal function, there is currently a lack of evidence.
Objective: This study aims to explore the safety and efficacy of laxatives as therapeutic agents for intestinal function recovery in CA, while further assessing the most suitable types of laxatives for this clinical context.
Methods: Utilizing the MIMIC-IV database, we conducted a retrospective cohort study categorizing patients into laxative and non-laxative groups. Propensity score matching (PSM) was applied to balance baseline characteristics. We classified confounders into prehospital and hospitalization categories, establishing three hierarchical adjustment models. Through multivariable Cox and logistic regression analyses, we assessed 30-day and extended mortality risks while evaluating laxative-associated safety outcomes. Time-dependent Cox regression analysis was utilized to assess the time-varying effect of laxative administration. Furthermore, we also comparatively analyzed the risk-benefit profiles of commonly used laxatives.
Results: 2604 patients were eligible for this study. After PSM, a total of 898 patients were average divided into two groups. Patients in the laxative group demonstrated a statistically significant reduction in 30-day mortality risk compared to the non-laxative group (HR = 0.686, 95%CI [0.550-0.855], P = 0.001). After applying time-dependent Cox regression analysis, the results remain consistent (HR = - 0.771 + 0.632 × ln[day + 1], 95%CI [0.528-0.835], P = 0.001). Meanwhile, laxative did not increase the risk of sepsis and Clostridium difficile infection but improved the bowel sounds recovery and increased the ICU-free day. Further subgroup analysis revealed that the use of docusate sodium (HR = 0.753, 95%CI [0.566-1.000], P = 0.050) may be associated with a decreased mortality risk.
Conclusion: Early using laxative to improve intestinal function is associated with improved survival outcomes. However, clinical application may be guided by the bowel sounds recovery and demonstrated tolerance to enteral feeding. This still requires further studies to confirm.
背景:尽管心脏骤停(CA)后护理取得了进展,但死亡率仍然很高。CA后的肠道功能障碍与不良临床结果相关。虽然泻药可能是恢复肠道功能的潜在治疗策略,但目前缺乏证据。目的:本研究旨在探讨泻药作为CA肠道功能恢复治疗药物的安全性和有效性,同时进一步评估最适合这种临床情况的泻药类型。方法:利用MIMIC-IV数据库进行回顾性队列研究,将患者分为泻药组和非泻药组。倾向评分匹配(PSM)用于平衡基线特征。我们将混杂因素分为院前和住院两类,建立了三种层次调整模型。通过多变量Cox和逻辑回归分析,我们评估了30天和延长的死亡风险,同时评估了泻药相关的安全性结果。采用时变Cox回归分析评估通便药的时变效应。此外,我们还比较分析了常用泻药的风险-收益概况。结果:2604例患者符合本研究的条件。经PSM治疗后,898例患者平均分为两组。通便药组患者30天死亡风险较未通便药组有统计学意义的降低(HR = 0.686, 95%CI [0.550-0.855], P = 0.001)。应用时间相关Cox回归分析后,结果一致(HR = - 0.771 + 0.632 × ln[day + 1], 95%CI [0.528-0.835], P = 0.001)。同时,泻药没有增加脓毒症和艰难梭菌感染的风险,但改善了肠音恢复,增加了无icu天数。进一步的亚组分析显示,使用docusate钠(HR = 0.753, 95%CI [0.566-1.000], P = 0.050)可能与降低死亡风险相关。结论:早期使用泻药改善肠道功能与改善生存预后相关。然而,临床应用可能以肠音恢复和肠内喂养耐受性为指导。这还需要进一步的研究来证实。
{"title":"Using laxative to recover intestinal function could improve the survival outcome for patients with cardiac arrest: a retrospective cohort study from MIMIC-IV database.","authors":"Jingwei Duan, Yuanchao Shi, Yufan Du, Dilu Li, Baomin Duan, Guoxing Wang","doi":"10.1186/s40560-026-00861-y","DOIUrl":"https://doi.org/10.1186/s40560-026-00861-y","url":null,"abstract":"<p><strong>Background: </strong>Despite advances in post-cardiac arrest (CA) care, mortality rates remain high. Intestinal dysfunction following CA is associated with adverse clinical outcomes. While laxatives might be a potential therapeutic strategy for restoring intestinal function, there is currently a lack of evidence.</p><p><strong>Objective: </strong>This study aims to explore the safety and efficacy of laxatives as therapeutic agents for intestinal function recovery in CA, while further assessing the most suitable types of laxatives for this clinical context.</p><p><strong>Methods: </strong>Utilizing the MIMIC-IV database, we conducted a retrospective cohort study categorizing patients into laxative and non-laxative groups. Propensity score matching (PSM) was applied to balance baseline characteristics. We classified confounders into prehospital and hospitalization categories, establishing three hierarchical adjustment models. Through multivariable Cox and logistic regression analyses, we assessed 30-day and extended mortality risks while evaluating laxative-associated safety outcomes. Time-dependent Cox regression analysis was utilized to assess the time-varying effect of laxative administration. Furthermore, we also comparatively analyzed the risk-benefit profiles of commonly used laxatives.</p><p><strong>Results: </strong>2604 patients were eligible for this study. After PSM, a total of 898 patients were average divided into two groups. Patients in the laxative group demonstrated a statistically significant reduction in 30-day mortality risk compared to the non-laxative group (HR = 0.686, 95%CI [0.550-0.855], P = 0.001). After applying time-dependent Cox regression analysis, the results remain consistent (HR = - 0.771 + 0.632 × ln[day + 1], 95%CI [0.528-0.835], P = 0.001). Meanwhile, laxative did not increase the risk of sepsis and Clostridium difficile infection but improved the bowel sounds recovery and increased the ICU-free day. Further subgroup analysis revealed that the use of docusate sodium (HR = 0.753, 95%CI [0.566-1.000], P = 0.050) may be associated with a decreased mortality risk.</p><p><strong>Conclusion: </strong>Early using laxative to improve intestinal function is associated with improved survival outcomes. However, clinical application may be guided by the bowel sounds recovery and demonstrated tolerance to enteral feeding. This still requires further studies to confirm.</p>","PeriodicalId":16123,"journal":{"name":"Journal of Intensive Care","volume":" ","pages":""},"PeriodicalIF":4.7,"publicationDate":"2026-02-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146150001","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-02-07DOI: 10.1186/s40560-026-00864-9
Matthias Manfred Deininger, Magdalena Ralser, Nico Haehn, Marius Huehn, Dmitrij Ziles, Gernot Marx, Catharina Conzen-Dilger, Anke Hoellig, Thomas Breuer
Background: Traumatic brain injury (TBI) is a major cause of trauma-related deaths. Systemic glucose and lactate levels reflect secondary metabolic derangements over time; however, most prognostic models rely on admission values. This study compared static and longitudinal indices of glucose, lactate, and their ratio in relation to ICU mortality.
Methods: This retrospective single-center study analyzed 479 non-diabetic adult patients with TBI admitted to a German university ICU (2013-2023). After 1:2 severity-balanced, outcome-stratified propensity score matching, 229 patients (150 survivors, 79 non-survivors) were included. Indices comprised admission values, means, clearance, time-weighted averages, variability, and dysglycemic burden. Outcome was ICU mortality, assessed using regression, mixed-effects modeling, and ROC analysis.
Results: Longitudinal indices showed stronger associations. Time-weighted average lactate was the best independent predictor (OR 14.70, 95% CI [5.41-39.98], p < 0.001, AUC 0.73). Time-weighted average glucose-lactate ratio also independently predicted ICU mortality (OR 0.75, 95% CI [0.66-0.86], p < 0.001). Non-survivors exhibited persistently higher glucose, lactate and lower ratios, with lactate significantly elevated on all first ten ICU days (all p < 0.05). Admission values, clearance and variability were not predictive after adjustment.
Conclusions: In critically ill non-diabetic patients with TBI, longitudinal time-weighted average lactate significantly outperformed admission values and glucose metrics for predicting ICU mortality in a severity-balanced cohort; the glucose-lactate ratio was associated but did not surpass lactate. These findings underscore the importance of longitudinal monitoring and support prioritizing lactate in multiparametric prognostic model to account for secondary injuries. Prospective validation is warranted to confirm external validity and assess therapeutic implications.
背景:创伤性脑损伤(TBI)是创伤相关死亡的主要原因。随着时间的推移,全身葡萄糖和乳酸水平反映继发性代谢紊乱;然而,大多数预后模型依赖于入院值。本研究比较了葡萄糖、乳酸的静态和纵向指标及其与ICU死亡率的关系。方法:本回顾性单中心研究分析了2013-2023年德国一所大学ICU收治的479例非糖尿病成年TBI患者。经1:2严重程度平衡、结果分层倾向评分匹配后,纳入229例患者(150例幸存者,79例非幸存者)。指标包括入院值、平均值、清除率、时间加权平均值、变异性和血糖异常负担。结果是ICU死亡率,采用回归、混合效应建模和ROC分析进行评估。结果:纵向指标相关性较强。时间加权平均乳酸是最好的独立预测因子(OR 14.70, 95% CI [5.41-39.98], p结论:在严重程度平衡的队列中,危重非糖尿病TBI患者,纵向时间加权平均乳酸显著优于入院值和血糖指标,预测ICU死亡率;葡萄糖-乳酸比值相关,但不超过乳酸。这些发现强调了纵向监测的重要性,并支持在多参数预后模型中优先考虑乳酸水平以解释继发性损伤。前瞻性验证是必要的,以确认外部有效性和评估治疗意义。
{"title":"Time-weighted lactate and glucose-lactate ratio outperform static values in ICU mortality prediction after traumatic brain injury: a retrospective cohort study.","authors":"Matthias Manfred Deininger, Magdalena Ralser, Nico Haehn, Marius Huehn, Dmitrij Ziles, Gernot Marx, Catharina Conzen-Dilger, Anke Hoellig, Thomas Breuer","doi":"10.1186/s40560-026-00864-9","DOIUrl":"https://doi.org/10.1186/s40560-026-00864-9","url":null,"abstract":"<p><strong>Background: </strong>Traumatic brain injury (TBI) is a major cause of trauma-related deaths. Systemic glucose and lactate levels reflect secondary metabolic derangements over time; however, most prognostic models rely on admission values. This study compared static and longitudinal indices of glucose, lactate, and their ratio in relation to ICU mortality.</p><p><strong>Methods: </strong>This retrospective single-center study analyzed 479 non-diabetic adult patients with TBI admitted to a German university ICU (2013-2023). After 1:2 severity-balanced, outcome-stratified propensity score matching, 229 patients (150 survivors, 79 non-survivors) were included. Indices comprised admission values, means, clearance, time-weighted averages, variability, and dysglycemic burden. Outcome was ICU mortality, assessed using regression, mixed-effects modeling, and ROC analysis.</p><p><strong>Results: </strong>Longitudinal indices showed stronger associations. Time-weighted average lactate was the best independent predictor (OR 14.70, 95% CI [5.41-39.98], p < 0.001, AUC 0.73). Time-weighted average glucose-lactate ratio also independently predicted ICU mortality (OR 0.75, 95% CI [0.66-0.86], p < 0.001). Non-survivors exhibited persistently higher glucose, lactate and lower ratios, with lactate significantly elevated on all first ten ICU days (all p < 0.05). Admission values, clearance and variability were not predictive after adjustment.</p><p><strong>Conclusions: </strong>In critically ill non-diabetic patients with TBI, longitudinal time-weighted average lactate significantly outperformed admission values and glucose metrics for predicting ICU mortality in a severity-balanced cohort; the glucose-lactate ratio was associated but did not surpass lactate. These findings underscore the importance of longitudinal monitoring and support prioritizing lactate in multiparametric prognostic model to account for secondary injuries. Prospective validation is warranted to confirm external validity and assess therapeutic implications.</p>","PeriodicalId":16123,"journal":{"name":"Journal of Intensive Care","volume":" ","pages":""},"PeriodicalIF":4.7,"publicationDate":"2026-02-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146137505","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Background: Tracheal intubation in critically ill adults is frequently complicated by severe physiological adverse events, particularly cardiovascular instability. Although fentanyl is commonly used for induction, observational data suggest that its use may increase the risk of post-intubation hypotension. However, the overall randomized evidence remains unclear. In this systematic review and meta-analysis of randomized controlled trials (RCTs), we hypothesized that induction regimens including fentanyl or its analogs would increase the risk of peri-intubation cardiovascular instability in critically ill patients.
Methods: We comprehensively searched PubMed, Embase, the Cochrane Library, ClinicalTrials.gov, and the WHO ICTRP from inception through October 31, 2025. Eligible studies were RCTs comparing an induction regimen including fentanyl or its analogs with one without them in critically ill adults undergoing tracheal intubation. The primary outcome was peri-intubation cardiovascular instability. Secondary outcomes included peri-intubation hypoxemia, successful intubation on the first attempt, duration of mechanical ventilation, ICU length of stay, and mortality. Random-effects meta-analyses were performed for all outcomes. Trial sequential analysis (TSA) was conducted for the primary outcome. Certainty of evidence was assessed using the GRADE approach.
Results: We included five RCTs and 515 participants. Two studies were judged to be low risk of bias, two raised some concerns, and one was at high risk of bias. Comparators included various induction agents and placebo. Definitions of peri-intubation cardiovascular instability also varied. The evidence was very uncertain regarding the effect of fentanyl on the risk of peri-intubation cardiovascular instability (risk ratio, 1.41; 95% confidence interval, 0.83-2.40; risk difference, 9.2% more; 95% confidence interval, 3.8% fewer to 31.3% more; very low certainty). In TSA, the required information size (n = 5586) was not reached, indicating the lack of statistical power. The certainty of evidence for pooled secondary outcomes was generally low or very low.
Conclusions: The effect of fentanyl on peri-intubation cardiovascular instability remains highly uncertain, with pooled estimates compatible with substantial harm, substantial benefit, or no effect. Current randomized evidence is insufficient to guide routine clinical practice, given their very low or low certainty and susceptibility to random error.
{"title":"Fentanyl as an induction agent for tracheal intubation in critically ill patients: a systematic review and meta-analysis.","authors":"Yuki Kotani, Takatoshi Koroki, Takeshi Nomura, Yoshiro Hayashi","doi":"10.1186/s40560-026-00866-7","DOIUrl":"https://doi.org/10.1186/s40560-026-00866-7","url":null,"abstract":"<p><strong>Background: </strong>Tracheal intubation in critically ill adults is frequently complicated by severe physiological adverse events, particularly cardiovascular instability. Although fentanyl is commonly used for induction, observational data suggest that its use may increase the risk of post-intubation hypotension. However, the overall randomized evidence remains unclear. In this systematic review and meta-analysis of randomized controlled trials (RCTs), we hypothesized that induction regimens including fentanyl or its analogs would increase the risk of peri-intubation cardiovascular instability in critically ill patients.</p><p><strong>Methods: </strong>We comprehensively searched PubMed, Embase, the Cochrane Library, ClinicalTrials.gov, and the WHO ICTRP from inception through October 31, 2025. Eligible studies were RCTs comparing an induction regimen including fentanyl or its analogs with one without them in critically ill adults undergoing tracheal intubation. The primary outcome was peri-intubation cardiovascular instability. Secondary outcomes included peri-intubation hypoxemia, successful intubation on the first attempt, duration of mechanical ventilation, ICU length of stay, and mortality. Random-effects meta-analyses were performed for all outcomes. Trial sequential analysis (TSA) was conducted for the primary outcome. Certainty of evidence was assessed using the GRADE approach.</p><p><strong>Results: </strong>We included five RCTs and 515 participants. Two studies were judged to be low risk of bias, two raised some concerns, and one was at high risk of bias. Comparators included various induction agents and placebo. Definitions of peri-intubation cardiovascular instability also varied. The evidence was very uncertain regarding the effect of fentanyl on the risk of peri-intubation cardiovascular instability (risk ratio, 1.41; 95% confidence interval, 0.83-2.40; risk difference, 9.2% more; 95% confidence interval, 3.8% fewer to 31.3% more; very low certainty). In TSA, the required information size (n = 5586) was not reached, indicating the lack of statistical power. The certainty of evidence for pooled secondary outcomes was generally low or very low.</p><p><strong>Conclusions: </strong>The effect of fentanyl on peri-intubation cardiovascular instability remains highly uncertain, with pooled estimates compatible with substantial harm, substantial benefit, or no effect. Current randomized evidence is insufficient to guide routine clinical practice, given their very low or low certainty and susceptibility to random error.</p><p><strong>Trial registration: </strong>PROSPERO (registration number: CRD420251241214).</p>","PeriodicalId":16123,"journal":{"name":"Journal of Intensive Care","volume":" ","pages":""},"PeriodicalIF":4.7,"publicationDate":"2026-02-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146137426","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-02-03DOI: 10.1186/s40560-025-00842-7
Muhammad Mohsin Sami, Ruqaiya Muhammad Naeem, Imran Zahid
{"title":"External ventricular drain-related meningitis: prediction model or early diagnostic tool?","authors":"Muhammad Mohsin Sami, Ruqaiya Muhammad Naeem, Imran Zahid","doi":"10.1186/s40560-025-00842-7","DOIUrl":"10.1186/s40560-025-00842-7","url":null,"abstract":"","PeriodicalId":16123,"journal":{"name":"Journal of Intensive Care","volume":"14 1","pages":"12"},"PeriodicalIF":4.7,"publicationDate":"2026-02-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12869999/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146113346","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Background: Sepsis is a critical determinant of mortality in critical patients. Antithrombin (AT) plays a pivotal role as a serine protease inhibitor with dual anticoagulant and anti-inflammatory functions, yet its precise role in prognostic stratification remains undefined. This study aimed to investigate the association between AT activity and clinical outcomes in sepsis and to identify critical prognostic thresholds.
Methods: We conducted a retrospective cohort study of 222 septic patients from the MIMIC-IV and MIMIC-III databases. AT activity was measured within the first 24 h following sepsis diagnosis, with the primary outcome defined as 28-day all-cause mortality. For preliminary description, AT activity was categorized into tertiles. The primary analysis utilized restricted cubic splines (RCS) to model the dose-response relationship and identify risk thresholds. Multivariable Cox regression models were employed to adjust for demographics, comorbidities, and SOFA score. Subgroup and survival analyses were performed to evaluate effect modification and visualize outcome differences across threshold-defined risk groups. To visually compare survival outcomes between patient groups defined by the RCS-derived risk thresholds, we generated Kaplan-Meier curves and employed log-rank tests.
Results: A non-linear relationship between AT activity and 28-day mortality was identified, with a marked increase in risk observed below approximately 55% in the overall cohort. Patients with AT activity < 55% had significantly higher 28-day mortality (34.2% vs. 14.4%, p = 0.001), ICU mortality (33.3% vs. 9.0%, p < 0.001), and incidences of disseminated intravascular coagulation (DIC) (22.5% vs. 3.6%, p < 0.001) and acute kidney injury (AKI) (78.4% vs. 62.2%, p = 0.013). Subgroup analysis revealed a significant interaction with hypertension. In the hypertensive subgroup, a similarly elevated risk zone was observed below approximately 64% AT activity. Hypertensive patients below this level had markedly increased 28-day mortality (42.3% vs. 9.62%, p < 0.001), ICU mortality (38.5% vs. 5.77%, p < 0.001), and incidences of DIC (19.2% vs. 1.92%, p < 0.001).
Conclusion: Reduced AT activity was significantly associated with higher mortality and organ dysfunction in sepsis. Risk thresholds were observed at approximately 55% for the overall cohort and 64% among hypertensive patients. Patients below these levels exhibited significantly increased mortality and higher incidences of DIC and AKI. These findings support AT activity as a prognostic biomarker for risk stratification and highlight its potential to inform future management strategies for high-risk patients.
{"title":"Association between antithrombin levels and prognosis in patients with sepsis: a retrospective cohort study based on the MIMIC-IV and MIMIC-III databases.","authors":"Bingkui Ren, Gang Zhou, Haiyan Xue, Siying Chen, Yuping Zhang, Guangjie Wang, Fengxue Zhu","doi":"10.1186/s40560-026-00862-x","DOIUrl":"https://doi.org/10.1186/s40560-026-00862-x","url":null,"abstract":"<p><strong>Background: </strong>Sepsis is a critical determinant of mortality in critical patients. Antithrombin (AT) plays a pivotal role as a serine protease inhibitor with dual anticoagulant and anti-inflammatory functions, yet its precise role in prognostic stratification remains undefined. This study aimed to investigate the association between AT activity and clinical outcomes in sepsis and to identify critical prognostic thresholds.</p><p><strong>Methods: </strong>We conducted a retrospective cohort study of 222 septic patients from the MIMIC-IV and MIMIC-III databases. AT activity was measured within the first 24 h following sepsis diagnosis, with the primary outcome defined as 28-day all-cause mortality. For preliminary description, AT activity was categorized into tertiles. The primary analysis utilized restricted cubic splines (RCS) to model the dose-response relationship and identify risk thresholds. Multivariable Cox regression models were employed to adjust for demographics, comorbidities, and SOFA score. Subgroup and survival analyses were performed to evaluate effect modification and visualize outcome differences across threshold-defined risk groups. To visually compare survival outcomes between patient groups defined by the RCS-derived risk thresholds, we generated Kaplan-Meier curves and employed log-rank tests.</p><p><strong>Results: </strong>A non-linear relationship between AT activity and 28-day mortality was identified, with a marked increase in risk observed below approximately 55% in the overall cohort. Patients with AT activity < 55% had significantly higher 28-day mortality (34.2% vs. 14.4%, p = 0.001), ICU mortality (33.3% vs. 9.0%, p < 0.001), and incidences of disseminated intravascular coagulation (DIC) (22.5% vs. 3.6%, p < 0.001) and acute kidney injury (AKI) (78.4% vs. 62.2%, p = 0.013). Subgroup analysis revealed a significant interaction with hypertension. In the hypertensive subgroup, a similarly elevated risk zone was observed below approximately 64% AT activity. Hypertensive patients below this level had markedly increased 28-day mortality (42.3% vs. 9.62%, p < 0.001), ICU mortality (38.5% vs. 5.77%, p < 0.001), and incidences of DIC (19.2% vs. 1.92%, p < 0.001).</p><p><strong>Conclusion: </strong>Reduced AT activity was significantly associated with higher mortality and organ dysfunction in sepsis. Risk thresholds were observed at approximately 55% for the overall cohort and 64% among hypertensive patients. Patients below these levels exhibited significantly increased mortality and higher incidences of DIC and AKI. These findings support AT activity as a prognostic biomarker for risk stratification and highlight its potential to inform future management strategies for high-risk patients.</p>","PeriodicalId":16123,"journal":{"name":"Journal of Intensive Care","volume":" ","pages":""},"PeriodicalIF":4.7,"publicationDate":"2026-02-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146105931","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-01-31DOI: 10.1186/s40560-026-00854-x
Arsah Asis, Darren McMahon, Shigeki Fujitani, Pedro Povoa, Alejandro Rodriguez, Luis Felipe Reyes, Ignacio Martin-Loeches
<p><strong>Background: </strong>Severe community-acquired pneumonia represents the most critical manifestation of pneumonia acquired outside the hospital and remains a major cause of intensive care admission and death worldwide. It is frequently complicated by acute respiratory failure, circulatory shock, and multiple organ dysfunction, with mortality commonly exceeding 25-40%. Despite progress in vaccination programmes, microbiological diagnostics, and critical care support, major uncertainties persist regarding early recognition, pathogen identification, antimicrobial selection and duration, management of co-infections, and assessment of treatment response. These challenges are amplified by increasing host heterogeneity and antimicrobial resistance.</p><p><strong>Main body: </strong>Contemporary epidemiological studies consistently demonstrate that mortality in severe community-acquired pneumonia is closely linked to the severity of organ dysfunction rather than to pulmonary involvement alone. In response, the recent international guideline definitions incorporate both respiratory and systemic criteria to standardise identification and guide early triage. However, these frameworks also reveal substantial variability related to host factors that influence clinical presentation, microbiological findings, and outcomes. Advanced age, sex, chronic cardiopulmonary disease, diabetes, frailty, and prior healthcare exposure modify risk, while immunocompromised populations-including transplant recipients, patients with malignancy, individuals receiving immunomodulatory therapies, and people living with Human Immunodeficiency Virus in resource-limited settings-face distinct diagnostic and therapeutic challenges. Accurate microbiological diagnosis remains difficult, with mixed or unidentified infections frequently encountered. Structured respiratory sampling and molecular diagnostic techniques, particularly lower respiratory tract multiplex polymerase chain reaction panels, have improved pathogen detection and support earlier optimisation of antimicrobial therapy. Biomarkers such as procalcitonin and C-reactive protein provide complementary information on disease trajectory and response to treatment, enabling more confident reassessment and earlier discontinuation of antibiotics when aligned with clinical improvement. Severity stratification using combined clinical scores, radiological extent, and laboratory markers refines prognostication and informs treatment intensity. Empiric antimicrobial therapy should be initiated promptly and individualised according to patient-specific risk factors for resistant pathogens, with systematic reassessment within 24-48 h. Adjunctive strategies, including advanced respiratory and haemodynamic support, corticosteroids in selected inflammatory phenotypes, and emerging host-directed therapies such as intravenous immunoglobulins, form part of a personalised management approach.</p><p><strong>Conclusions: </strong>An integra
{"title":"Severe community-acquired pneumonia: an integral approach.","authors":"Arsah Asis, Darren McMahon, Shigeki Fujitani, Pedro Povoa, Alejandro Rodriguez, Luis Felipe Reyes, Ignacio Martin-Loeches","doi":"10.1186/s40560-026-00854-x","DOIUrl":"https://doi.org/10.1186/s40560-026-00854-x","url":null,"abstract":"<p><strong>Background: </strong>Severe community-acquired pneumonia represents the most critical manifestation of pneumonia acquired outside the hospital and remains a major cause of intensive care admission and death worldwide. It is frequently complicated by acute respiratory failure, circulatory shock, and multiple organ dysfunction, with mortality commonly exceeding 25-40%. Despite progress in vaccination programmes, microbiological diagnostics, and critical care support, major uncertainties persist regarding early recognition, pathogen identification, antimicrobial selection and duration, management of co-infections, and assessment of treatment response. These challenges are amplified by increasing host heterogeneity and antimicrobial resistance.</p><p><strong>Main body: </strong>Contemporary epidemiological studies consistently demonstrate that mortality in severe community-acquired pneumonia is closely linked to the severity of organ dysfunction rather than to pulmonary involvement alone. In response, the recent international guideline definitions incorporate both respiratory and systemic criteria to standardise identification and guide early triage. However, these frameworks also reveal substantial variability related to host factors that influence clinical presentation, microbiological findings, and outcomes. Advanced age, sex, chronic cardiopulmonary disease, diabetes, frailty, and prior healthcare exposure modify risk, while immunocompromised populations-including transplant recipients, patients with malignancy, individuals receiving immunomodulatory therapies, and people living with Human Immunodeficiency Virus in resource-limited settings-face distinct diagnostic and therapeutic challenges. Accurate microbiological diagnosis remains difficult, with mixed or unidentified infections frequently encountered. Structured respiratory sampling and molecular diagnostic techniques, particularly lower respiratory tract multiplex polymerase chain reaction panels, have improved pathogen detection and support earlier optimisation of antimicrobial therapy. Biomarkers such as procalcitonin and C-reactive protein provide complementary information on disease trajectory and response to treatment, enabling more confident reassessment and earlier discontinuation of antibiotics when aligned with clinical improvement. Severity stratification using combined clinical scores, radiological extent, and laboratory markers refines prognostication and informs treatment intensity. Empiric antimicrobial therapy should be initiated promptly and individualised according to patient-specific risk factors for resistant pathogens, with systematic reassessment within 24-48 h. Adjunctive strategies, including advanced respiratory and haemodynamic support, corticosteroids in selected inflammatory phenotypes, and emerging host-directed therapies such as intravenous immunoglobulins, form part of a personalised management approach.</p><p><strong>Conclusions: </strong>An integra","PeriodicalId":16123,"journal":{"name":"Journal of Intensive Care","volume":" ","pages":""},"PeriodicalIF":4.7,"publicationDate":"2026-01-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146097131","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-01-28DOI: 10.1186/s40560-026-00859-6
Jun Hagiwara, Keitaro Yoshioka, Kanako Ito-Hagiwara, Yusuke Endo, Daniel Jafari, Daniel M Rolston, Cyrus E Kuschner, Lance B Becker, Kei Hayashida
Infections are frequent after cardiac arrest and materially affect post-ICU care and outcomes. Diagnostic uncertainty is heightened by post-cardiac arrest syndrome (PCAS)-hypoxic-ischemic brain injury, myocardial dysfunction, systemic ischemia-reperfusion injury, and immune dysregulation-and by sedation and targeted temperature management (TTM), which can mask clinical signs and modulate host defenses. Pneumonia predominates; bloodstream infection and intra-abdominal or hepatobiliary infections are under-recognized, especially in device-dependent or extracorporeal membrane oxygenation (ECMO)-treated patients. Conventional biomarkers such as C-reactive protein and procalcitonin show reduced infection specificity early after return of spontaneous circulation; therefore, single timepoint cutoffs are unreliable, and serial trajectories interpreted with clinical examination, microbiology, and imaging are preferred. Risk scores (e.g., Sequential Organ Failure Assessment [SOFA], Clinical Pulmonary Infection Score [CPIS]) may support stratification but are insufficient for definitive diagnosis. Observational cohorts report higher pneumonia rates with TTM, and temperature control can blunt fever and leukocytosis and alter cytokine and biomarker kinetics, complicating timely recognition. Prevention should emphasize protocolized bundles, including hand hygiene and asepsis, head-of-bed elevation, structured oral care per local policy, minimization of sedation with spontaneous breathing trials, and early removal of unnecessary devices, within an antimicrobial stewardship framework that supports early de-escalation once cultures and trajectories clarify etiology. Procalcitonin-guided early discontinuation reduces antibiotic exposure in general critical-care populations; in PCAS, use should prioritize serial trends integrated with clinical context rather than single thresholds. No fixed algorithm is prescribed; instead, practical considerations are presented to guide diagnostic practice, emphasizing early microbiological sampling and imaging, integration of serial biomarker trajectories with clinical assessment, and timely de-escalation as the clinical picture clarifies, without endorsing single-test cutoffs. Priorities include quantifying infection-attributable morbidity and mortality; developing and validating PCAS-specific biomarkers and composite decision tools, including electronic health record-based early warning models; evaluating short post-intubation prophylaxis in selected high-risk patients; optimizing TTM parameters (target temperature, duration, rewarming rate); and systematically characterizing under-recognized infections. A protocol-driven, multimodal program that integrates prevention, standardized diagnostics, and stewardship is required to deliver timely, appropriate therapy and improve outcomes after cardiac arrest.
{"title":"Optimizing infection management after cardiac arrest: addressing diagnostic uncertainty and therapeutic dilemmas-a narrative review.","authors":"Jun Hagiwara, Keitaro Yoshioka, Kanako Ito-Hagiwara, Yusuke Endo, Daniel Jafari, Daniel M Rolston, Cyrus E Kuschner, Lance B Becker, Kei Hayashida","doi":"10.1186/s40560-026-00859-6","DOIUrl":"https://doi.org/10.1186/s40560-026-00859-6","url":null,"abstract":"<p><p>Infections are frequent after cardiac arrest and materially affect post-ICU care and outcomes. Diagnostic uncertainty is heightened by post-cardiac arrest syndrome (PCAS)-hypoxic-ischemic brain injury, myocardial dysfunction, systemic ischemia-reperfusion injury, and immune dysregulation-and by sedation and targeted temperature management (TTM), which can mask clinical signs and modulate host defenses. Pneumonia predominates; bloodstream infection and intra-abdominal or hepatobiliary infections are under-recognized, especially in device-dependent or extracorporeal membrane oxygenation (ECMO)-treated patients. Conventional biomarkers such as C-reactive protein and procalcitonin show reduced infection specificity early after return of spontaneous circulation; therefore, single timepoint cutoffs are unreliable, and serial trajectories interpreted with clinical examination, microbiology, and imaging are preferred. Risk scores (e.g., Sequential Organ Failure Assessment [SOFA], Clinical Pulmonary Infection Score [CPIS]) may support stratification but are insufficient for definitive diagnosis. Observational cohorts report higher pneumonia rates with TTM, and temperature control can blunt fever and leukocytosis and alter cytokine and biomarker kinetics, complicating timely recognition. Prevention should emphasize protocolized bundles, including hand hygiene and asepsis, head-of-bed elevation, structured oral care per local policy, minimization of sedation with spontaneous breathing trials, and early removal of unnecessary devices, within an antimicrobial stewardship framework that supports early de-escalation once cultures and trajectories clarify etiology. Procalcitonin-guided early discontinuation reduces antibiotic exposure in general critical-care populations; in PCAS, use should prioritize serial trends integrated with clinical context rather than single thresholds. No fixed algorithm is prescribed; instead, practical considerations are presented to guide diagnostic practice, emphasizing early microbiological sampling and imaging, integration of serial biomarker trajectories with clinical assessment, and timely de-escalation as the clinical picture clarifies, without endorsing single-test cutoffs. Priorities include quantifying infection-attributable morbidity and mortality; developing and validating PCAS-specific biomarkers and composite decision tools, including electronic health record-based early warning models; evaluating short post-intubation prophylaxis in selected high-risk patients; optimizing TTM parameters (target temperature, duration, rewarming rate); and systematically characterizing under-recognized infections. A protocol-driven, multimodal program that integrates prevention, standardized diagnostics, and stewardship is required to deliver timely, appropriate therapy and improve outcomes after cardiac arrest.</p>","PeriodicalId":16123,"journal":{"name":"Journal of Intensive Care","volume":" ","pages":""},"PeriodicalIF":4.7,"publicationDate":"2026-01-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146064334","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Background: Traumatic brain injury (TBI) is a major public health concern associated with substantial morbidity and mortality. In Japan, carbazochrome sodium sulfonate (CSS) is widely used, often in combination with tranexamic acid (TXA), for the management of various types of bleeding; however, studies on the effectiveness of CSS in TBI are scarce. Therefore, this study aimed to investigate the association between the use of CSS plus TXA versus TXA alone and the clinical outcomes in patients with TBI.
Methods: This observational study was conducted using data retrieved from the Japanese Diagnosis Procedure Combination database between July 2010 and March 2022. We enrolled adult patients aged ≥ 16 years diagnosed with TBI who received TXA on the day of admission. Patients with chronic subdural hematoma, suspected TBI diagnosis, or severe extracranial trauma were excluded. The exposure was CSS plus TXA administration on the day of admission, with TXA monotherapy assigned as the control. The primary outcome was 28-day in-hospital mortality, and the secondary outcomes were 7-day in-hospital mortality, overall in-hospital mortality, consciousness at discharge, and length of hospital stay. We used propensity-score overlap weighting to balance patient characteristics between the groups.
Results: This study included 150,026 patients. Of these, 17,212 (11.5%) received TXA alone, and 132,814 (88.5%) received CSS plus TXA. After propensity score overlap weighting, the primary outcome did not differ significantly between the TXA-only and CSS plus TXA groups (11.7% vs. 11.9%; risk difference, 0.1%; 95% CI - 0.4 to 0.7%). The secondary outcomes were also comparable between the two groups. However, the subgroup analysis restricted to unarousable patients (Japan Coma Scale 100-300) revealed a significant reduction in the 7-day mortality in the CSS plus TXA group.
Conclusions: Combined treatment with CSS and TXA was not associated with better clinical outcomes in terms of in-hospital mortality, consciousness at discharge, or length of hospital stay in hospitalized adult patients with TBI compared with TXA therapy alone. Routine use of CSS may not be recommended.
背景:外伤性脑损伤(TBI)是与大量发病率和死亡率相关的主要公共卫生问题。在日本,咔唑铬磺酸钠(CSS)被广泛使用,通常与氨甲环酸(TXA)联合使用,用于治疗各种类型的出血;然而,关于CSS在TBI中的有效性的研究很少。因此,本研究旨在探讨CSS联合TXA与单独使用TXA与TBI患者临床结局之间的关系。方法:本观察性研究使用2010年7月至2022年3月从日本诊断程序组合数据库检索的数据进行。我们招募了年龄≥16岁诊断为TBI并在入院当天接受TXA治疗的成年患者。排除有慢性硬膜下血肿、疑似脑外伤或严重颅外外伤的患者。在入院当天,暴露为CSS加TXA治疗,TXA单药治疗作为对照。主要结局是28天住院死亡率,次要结局是7天住院死亡率、总体住院死亡率、出院时意识和住院时间。我们使用倾向评分重叠加权来平衡各组之间的患者特征。结果:本研究纳入150,026例患者。其中,17212例(11.5%)单独接受TXA治疗,132814例(88.5%)接受CSS加TXA治疗。在倾向评分重叠加权后,主要结局在仅使用TXA和CSS加TXA组之间没有显著差异(11.7% vs 11.9%;风险差异为0.1%;95% CI - 0.4 - 0.7%)。两组间的次要结果也具有可比性。然而,亚组分析仅限于不能醒来的患者(日本昏迷量表100-300),结果显示CSS加TXA组7天死亡率显著降低。结论:与单独TXA治疗相比,在住院成年TBI患者的住院死亡率、出院时意识或住院时间方面,CSS和TXA联合治疗与更好的临床结果无关。不建议常规使用CSS。
{"title":"Outcomes of combined carbazochrome sodium sulfonate plus tranexamic acid therapy versus tranexamic acid monotherapy in traumatic brain injury: a retrospective cohort study in Japan.","authors":"Jinsuke Mizuno, Yoshihisa Miyamoto, Yuichiro Matsuo, Kiyohide Fushimi, Ryota Inokuchi, Kent Doi, Hideo Yasunaga","doi":"10.1186/s40560-026-00855-w","DOIUrl":"https://doi.org/10.1186/s40560-026-00855-w","url":null,"abstract":"<p><strong>Background: </strong>Traumatic brain injury (TBI) is a major public health concern associated with substantial morbidity and mortality. In Japan, carbazochrome sodium sulfonate (CSS) is widely used, often in combination with tranexamic acid (TXA), for the management of various types of bleeding; however, studies on the effectiveness of CSS in TBI are scarce. Therefore, this study aimed to investigate the association between the use of CSS plus TXA versus TXA alone and the clinical outcomes in patients with TBI.</p><p><strong>Methods: </strong>This observational study was conducted using data retrieved from the Japanese Diagnosis Procedure Combination database between July 2010 and March 2022. We enrolled adult patients aged ≥ 16 years diagnosed with TBI who received TXA on the day of admission. Patients with chronic subdural hematoma, suspected TBI diagnosis, or severe extracranial trauma were excluded. The exposure was CSS plus TXA administration on the day of admission, with TXA monotherapy assigned as the control. The primary outcome was 28-day in-hospital mortality, and the secondary outcomes were 7-day in-hospital mortality, overall in-hospital mortality, consciousness at discharge, and length of hospital stay. We used propensity-score overlap weighting to balance patient characteristics between the groups.</p><p><strong>Results: </strong>This study included 150,026 patients. Of these, 17,212 (11.5%) received TXA alone, and 132,814 (88.5%) received CSS plus TXA. After propensity score overlap weighting, the primary outcome did not differ significantly between the TXA-only and CSS plus TXA groups (11.7% vs. 11.9%; risk difference, 0.1%; 95% CI - 0.4 to 0.7%). The secondary outcomes were also comparable between the two groups. However, the subgroup analysis restricted to unarousable patients (Japan Coma Scale 100-300) revealed a significant reduction in the 7-day mortality in the CSS plus TXA group.</p><p><strong>Conclusions: </strong>Combined treatment with CSS and TXA was not associated with better clinical outcomes in terms of in-hospital mortality, consciousness at discharge, or length of hospital stay in hospitalized adult patients with TBI compared with TXA therapy alone. Routine use of CSS may not be recommended.</p>","PeriodicalId":16123,"journal":{"name":"Journal of Intensive Care","volume":" ","pages":""},"PeriodicalIF":4.7,"publicationDate":"2026-01-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146064379","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-01-26DOI: 10.1186/s40560-026-00851-0
Maxime Théo Aparicio, Sylvain Diop, Roman Mounier
In this comment, we aim to offer some perspective on the work of Raffenot et al. entitled "Risk factors for nosocomial meningitis in patients with external ventricular drainages". After highlighting the main findings of their study, we discuss the predictive model as well as the disease definition they used.
{"title":"Comments on: risk factors for nosocomial meningitis in patients with external ventricular drainages.","authors":"Maxime Théo Aparicio, Sylvain Diop, Roman Mounier","doi":"10.1186/s40560-026-00851-0","DOIUrl":"10.1186/s40560-026-00851-0","url":null,"abstract":"<p><p>In this comment, we aim to offer some perspective on the work of Raffenot et al. entitled \"Risk factors for nosocomial meningitis in patients with external ventricular drainages\". After highlighting the main findings of their study, we discuss the predictive model as well as the disease definition they used.</p>","PeriodicalId":16123,"journal":{"name":"Journal of Intensive Care","volume":"14 1","pages":"7"},"PeriodicalIF":4.7,"publicationDate":"2026-01-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12833928/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146052508","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}